The ability to activate the immune system powerfully and precisely against serious diseases is not limited to cancer. It has broad potential in other markets–from infectious diseases, to allergic responses and beyond.
We are working with multiple partners to develop a clinical asset pipeline outside of oncology. The unique MOA that underscores our formulations may have specific utility in public health threats such as virulent malaria and the Zika virus, and complex indications with limited if any treatment options such as respiratory syncytial virus (RSV).
DPX-RSV, our innovative candidate for this indication, has completed a Phase 1 clinical trial with strong positive results in this difficult indication. We are currently assessing the best possible path forward for its further clinical development.